Kymriah (tisagenlecleucel-T) / University of Pennsylvania, Novartis  >>  Phase 3
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kymriah (tisagenlecleucel-T) / Novartis
NCT03123939 / 2016-001991-31: Phase III B in Acute Lymphoblastic Leukemia

Completed
3
69
Europe, Canada, Japan
CTL019
Novartis Pharmaceuticals
Acute Lymphoblastic Leukemia
10/20
10/20
NCT04094311: Study of Out of Specification for Tisagenlecleucel

Recruiting
3
200
Canada, Japan
CTL019, Tisagenlecleucel
Novartis Pharmaceuticals
B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma
04/25
04/25
OBERON, NCT03628053: Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia

Calendar Jan 2025 - Dec 2025: From OBERON trial for r/r ALL
Withdrawn
3
0
NA
Tisagenlecleucel, CTL019, KYMRIAH, Blinatumomab, BLINCYTO, Inotuzumab, BESPONSA, Inotuzumab ozogamicin
Novartis Pharmaceuticals
Acute Lymphoblastic Leukemia
10/25
01/26
BELINDA, NCT03570892 / 2016-002966-29: Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma

Checkmark From BELINDA trial for 2L DLBCL [Did not met primary end point]
Aug 2021 - Aug 2021: From BELINDA trial for 2L DLBCL [Did not met primary end point]
Active, not recruiting
3
331
Europe, Japan, US, RoW
Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy, Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)
Novartis Pharmaceuticals
Non-Hodgkin Lymphoma
02/26
02/26
LEDA, NCT05888493: A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma

Recruiting
3
108
Europe, RoW
Tisagenlecleucel, CTL019, Lenalidomide and rituximab (R2) in 28-day cycles for up to 12 cycles., R2, Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or prednisolone (R-CHOP) in 21-day cycles for 6 to 8 cycles, R-CHOP, Lymphodepleting chemotherapy, Corticosteroids and/or Radiation (Bridging therapy)
Novartis Pharmaceuticals
Follicular Lymphoma (FL)
07/28
02/29

Download Options